Karolina Luczkowska
Overview
Explore the profile of Karolina Luczkowska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kulig P, Luczkowska K, Machalinski B, Baumert B
Sci Rep
. 2024 Oct;
14(1):23559.
PMID: 39384864
Lenalidomide (LEN) is widely used immunomodulatory drug (IMiD). Nonetheless, despite its efficacy, over time patients become resistant to LEN and relapse. Due to high clinical relevance, drug resistance in MM...
2.
Luczkowska K, Zhou Y, Ramos-Lobo A, Brun T, Maechler P
J Biol Chem
. 2024 Jun;
300(7):107473.
PMID: 38879007
Provision of amino acids to the liver is instrumental for gluconeogenesis while it requires safe disposal of the amino group. The mitochondrial enzyme glutamate dehydrogenase (GDH) is central for hepatic...
3.
Janowski M, Luczkowska K, Gniot M, Lewandowski K, Safranow K, Helbig G, et al.
J Clin Med
. 2024 Apr;
13(8).
PMID: 38673624
: The effective treatment of chronic myeloid leukemia leads to the restoration of proper immune system function. We aimed to investigate fluctuations in circulating cytokines, angiogenic factors and complement components...
4.
Dabkowska M, Stukan I, Kosiorowska A, Szatanik A, Luczkowska K, Machalinska A, et al.
Int J Biol Macromol
. 2024 Mar;
265(Pt 2):130726.
PMID: 38490392
The utilization of neurotrophins in medicine shows significant potential for addressing neurodegenerative conditions, such as age-related macular degeneration (AMD). However, the therapeutic use of neurotrophins has been restricted due to...
5.
Luczkowska K, Kulig P, Baumert B, Machalinski B
Nutrients
. 2024 Jan;
16(1).
PMID: 38201971
Multiple myeloma (MM) is a plasma cell malignancy that, despite recent advances in therapy, continues to pose a major challenge to hematologists. Currently, different classes of drugs are applied to...
6.
Kulig P, Luczkowska K, Bakinowska E, Baumert B, Machalinski B
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201512
Bortezomib (BTZ) is widely implemented in the treatment of multiple myeloma (MM). Its main mechanism of action is very well established. BTZ selectively and reversibly inhibits the 26S proteasome. More...
7.
Pius-Sadowska E, Kulig P, Niedzwiedz A, Baumert B, Luczkowska K, Roginska D, et al.
Int J Mol Sci
. 2023 Dec;
24(23).
PMID: 38069327
The pathophysiology of the severe course of COVID-19 is multifactorial and not entirely elucidated. However, it is well known that the hyperinflammatory response and cytokine storm are paramount events leading...
8.
Luczkowska K, Kulig P, Rusinska K, Baumert B, Machalinski B
Int J Mol Sci
. 2023 Dec;
24(23).
PMID: 38069103
Multiple myeloma (MM) is a plasma cell malignancy that accounts for 1% of all cancers and is the second-most-common hematological neoplasm. Bortezomib (BTZ) is a proteasome inhibitor widely implemented in...
9.
Rogulska K, Wojciechowska-Koszko I, Krasnodebska-Szponder B, Kwiatkowski P, Roszkowska P, Dolegowska B, et al.
Int J Mol Sci
. 2023 Aug;
24(15).
PMID: 37569301
Intestinal trefoil factor 3 (TFF3) is a protein secreted by many cell types, and its serum and urine levels vary in patients with kidney disease. Therefore, the present study aimed...
10.
Rudkowski K, Waszczuk K, Tyburski E, Rek-Owodzin K, Plichta P, Podwalski P, et al.
J Clin Med
. 2023 Feb;
12(4).
PMID: 36836111
Evidence suggests a role of the immune system in the pathogenesis of a number of mental conditions, including schizophrenia (SCH). In terms of physiology, aside from its crucial protective function,...